Trevi Therapeutics Announces Results from Phase 2b/3 PRISM O

Continued reduction in WI-NRS observed among participants who remained in the study through 52 weeks of treatmentSafety data over 52 weeks: treatm...

Related Keywords

Germany , Berlin , United States , Katie Mcmanus , Rosalia Scampoli , Exchange Commission , European Academy Of Dermatology Venereology , Prnewswire Trevi Therapeutics Inc , Us Drug Enforcement Agency , Trevi Therapeutics Inc , Linkedin , Nasdaq , European Academy , Professor Elke Weisshaar , Jennifer Good , Pruritus Relief , Itch Scratch Modulation , Events Reported During , Week Open Label , Worst Itch Numerical Rating Scale , Trevi Therapeutics , Private Securities Litigation Reform Act ,